Status
Conditions
Treatments
About
Primary Objective:
To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months
To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to first subsequent therapy, rate of very good partial response or better, rate of complete response (CR) or better of isatuximab patients with RRMM in routine clinical practice
To assess the profile of patients (demographic, disease characteristics, comorbidities and prior MM treatment history) who are treated with isatuximab in routine clinical practice
To describe safety of isatuximab in routine clinical practice (based on adverse event [AE] reporting)
To assess quality of life (QoL) using the European Organization for Research and Treatment of Cancer (EORTC) 30 item core questionnaire (QLQ C30) and the accompanying 20 item myeloma questionnaire module (QLQ MY20)
Secondary Objective:
Not applicable
Full description
Duration per participant is 2.5 years
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Age ≥18 years
Most important exclusion criteria for potential participants:
Patients who are receiving isatuximab for an indication other than RRMM
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
586 participants in 1 patient group
Loading...
Central trial contact
Trial Transparency email recommended (Toll free number for US & Canada)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal